BioLife Solutions, Inc. (NASDAQ:BLFS) Holdings Raised by Millennium Management LLC

Millennium Management LLC lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 49.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,145,347 shares of the medical equipment provider's stock after purchasing an additional 377,111 shares during the quarter. Millennium Management LLC owned about 2.47% of BioLife Solutions worth $29,733,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BLFS. Steward Partners Investment Advisory LLC acquired a new position in shares of BioLife Solutions during the fourth quarter worth approximately $26,000. 1620 Investment Advisors Inc. raised its stake in BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after acquiring an additional 675 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock valued at $117,000 after acquiring an additional 950 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in BioLife Solutions during the 4th quarter worth $171,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of BioLife Solutions in the fourth quarter worth $201,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other BioLife Solutions news, insider Sarah Aebersold sold 1,091 shares of the business's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $27,275.00. Following the sale, the insider now owns 58,816 shares in the company, valued at approximately $1,470,400. The trade was a 1.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Todd Berard sold 1,577 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $39,425.00. Following the sale, the chief marketing officer now directly owns 104,961 shares of the company's stock, valued at $2,624,025. This represents a 1.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,696 shares of company stock worth $1,665,094. Corporate insiders own 2.20% of the company's stock.

BioLife Solutions Price Performance

BLFS stock traded up $0.01 during trading hours on Thursday, hitting $22.10. 265,606 shares of the stock traded hands, compared to its average volume of 385,257. The stock has a 50-day simple moving average of $23.35 and a 200 day simple moving average of $25.26. The company has a market cap of $1.05 billion, a P/E ratio of -20.85 and a beta of 2.01. BioLife Solutions, Inc. has a one year low of $18.70 and a one year high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The company had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. Equities analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.